Prostate Cancer Clinical Trial
Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer
|Source||Weill Medical College of Cornell University|
|Contact||Sharanya Chandrasekhar, M.S.|
|Start date||September 2016|
|Completion date||September 2019|
Patients with low-risk or favorable intermediate-risk prostate cancer as defined by 1.2016 NCCN criteria will be eligible to participate on this study.
This is a randomized, two arm study for patients with low-risk or favorable
intermediate-risk prostate cancer as defined by 1.2016 NCCN criteria.
Patients will be randomized to either rectal spacer placement or endorectal balloon placement, daily prior to each radiation treatment.
1. Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.
2. Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.
This study plans to enroll a total of 40 patients with an accrual period of 4 years.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
|Recruiting||NCT03177759 - Living With Prostate Cancer (LPC)||N/A|
|Completed||NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data||N/A|
|Not yet recruiting||NCT03160365 - Innovative Planning and Guidance System for Prostate Focal Brachytherapy||N/A|
|Active, not recruiting||NCT02124668 - A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy||Phase 2|
|Completed||NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis||N/A|
|Active, not recruiting||NCT00779168 - White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy||Phase 1|
|Recruiting||NCT01990196 - Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer||Phase 2|
|Recruiting||NCT02766543 - Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer||Phase 2|
|Not yet recruiting||NCT03157947 - Culturally Tailored Decision Aid for Hispanic Patients Diagnosed With Prostate Cancer||N/A|
|Recruiting||NCT02919111 - Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients||Phase 2/Phase 3|
|Recruiting||NCT02766686 - Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons||N/A|
|Recruiting||NCT02543255 - Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)||Phase 2|
|Recruiting||NCT02917161 - Prostatic Artery Embolization Before Radical Prostatectomy in Prostate Cancer: A Proof-of-concept Study||N/A|
|Recruiting||NCT02886598 - Safety and Efficacy of Firmagon® (Degarelix) for Injection||N/A|
|Recruiting||NCT02916537 - A Phase 1 Trial for Safety and Imaging Evaluation of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA)||Phase 1|
|Recruiting||NCT02918357 - Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence||Phase 2/Phase 3|
|Recruiting||NCT02747342 - A Phase 1 Trial of SHR3680 in Prostate Cancer as Monotherapy||Phase 1|
|Recruiting||NCT02906241 - PACCT: Partnering Around Cancer Clinical Trials||N/A|
|Enrolling by invitation||NCT02840552 - The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer||Phase 3|
|Not yet recruiting||NCT02911649 - Reducing Sedentary Behaviour With Technology||N/A|